Vesalius’s “Proven Investment Strategy” Reflected In Largest Fund Close To Date
European fund manager Vesalius has closed its third fund with €120m. Its managers believe their strategy of investing in maturing companies has been the key to attracting commitments, including from the European Investment Fund.
You may also be interested in...
Private Company Edition: A new VC fund emerges for European biopharma firms and a previously announced fund gains a new UK investor. Also, Encoded Therapeutics leads recent venture financings with a $104m series C round.
An international VC, Vesalius Biocapital, is to invest in start-up life sciences and biotech companies in the western European country that is developing an entrepreneurial ecosystem.
In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.